West Pharmaceutical Services (WST) is back in focus after recent share price swings, with the stock closing at US$348.48. Investors are weighing this move against its performance over the past month and the past three months.

Over a longer stretch, West Pharmaceutical Services has seen a strong year-to-date share price return of 26.08%, alongside a 1-year total shareholder return of 42.97%. However, the 3-year and 5-year total shareholder returns show declines, which suggests that momentum has picked up more recently rather than over the longer term.

Compare West Pharmaceutical Services with a hand picked 49 high quality undervalued stocks that also show fresh momentum after recent share price moves.

With West Pharmaceutical Services trading below the average analyst price target yet above an estimated intrinsic value, recent momentum raises a clear tension. Is the market being too cautious or simply realistic about what you are paying for?

Most Popular Narrative: 13.7% Undervalued

On the most followed narrative, West Pharmaceutical Services has a fair value of about $404, which sits above the last close at $348.48. That gap is built on a detailed view of how high value components and newer drug delivery demand could shape the company in the coming years.

The continued growth in GLP-1s, which made up about 7% of total revenues in the first quarter, and the company's ability to capitalize on significant opportunities in this market could drive revenue and earnings growth. The anticipated high single-digit growth rate for Biologics HVP components in the second half of 2025, despite initial destocking challenges, shows potential for revenue acceleration and earnings improvement.

Want to understand why this narrative still treats a premium price as reasonable for West Pharmaceutical Services? The story connects steady top line growth, rising profit margins and a future earnings profile that leans on high value products and GLP 1 exposure. The key is how these elements are expected to compound together over time.

Result: Fair Value of $404 (UNDERVALUED)

However, the West Pharmaceutical Services narrative could be challenged if GLP 1 demand softens, or if contract manufacturing margin pressure from exiting CGM work lasts longer than expected.

Another View On West Pharmaceutical Services

There is a catch. While the narrative points to West Pharmaceutical Services trading below fair value, the stock changes hands at a P/E of 43.4x versus 40.5x for peers and a fair ratio of 22.3x. That gap points to real valuation risk if sentiment cools.

Given that, it helps to ask whether you prefer the story that says the stock is 13.7% undervalued, or the one that flags a P/E almost double the fair ratio. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mixed signals around West Pharmaceutical Services mean sentiment is far from settled, so move quickly, review the data, and weigh the 2 key rewards for yourself.

Looking for more investment ideas beyond West Pharmaceutical Services?

If West Pharmaceutical Services has your attention, do not stop there. Use the Simply Wall Street Screener to uncover other stocks that could round out your watchlist.

• Target higher quality at a discount by scanning a 49 high quality undervalued stocks that already clear basic financial strength checks.
• Prioritise stability and capital protection by reviewing a 74 resilient stocks with low risk scores that still offer meaningful upside potential.
• Spot tomorrow's potential leaders early by working through a 18 high quality undiscovered gems before they hit everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.